3173 results for «3424»
3173 results
Advancing the standard of care in PCI with Bioadaptor: from simple to complex
21 May 2025 – From EuroPCR 2025
This session provides an in-depth overview of Bioadapter technology and its potential to overcome the limitations of current drug-eluting stents (DES) in percutaneous coronary intervention (PCI). Speakers present data from recent trials, including the Bioadapter RCT and the Infinity Sweetheart study, demonstrating a reduction in target lesion...
Contemporary challenges in acute coronary syndromes
20 May 2025 – From EuroPCR 2025
Examine contemporary challenges in acute coronary syndromes (ACS) through recent trials and studies. Topics include long-term outcomes of deferred stenting, thrombectomy techniques, PCI in cardiogenic shock, and revascularisation strategies, providing a comprehensive update for clinical practice.
How to build a tricuspid programme?
20 May 2025 – From EuroPCR 2025
Learn how to build a successful tricuspid valve programme with a focus on patient screening protocols, heart team roles, and post-procedural management. Gain expert perspectives on organizational requirements, referral optimization, multidisciplinary collaboration, and quality assessment for tricuspid interventions.
Align for the future with the Myval Octapro transcatheter heart valve series
20 May 2025 – From EuroPCR 2025
This EuroPCR 2025 session offers a practical and evidence-based update on the Myval Octapro THV. Learn step-by-step techniques for valve-in-valve TAVI using the OctaAlign approach, and understand how intermediate sizes and precise deployment contribute to optimised hemodynamics and long-term durability.
Clinical insights are backed by key data...
Challenging scenarios in patient with multivessel disease
20 May 2025 – From EuroPCR 2025
Explore challenging clinical scenarios in patients with multivessel coronary artery disease. This session presents complex cases such as coronary aneurysms, failed bypass grafts, limitations of intravascular lithotripsy, and rare pathologies like Takayasu’s arteritis, highlighting decision-making and advanced intervention strategies.
Broadening OPTIONs for LAA closure: innovations and outcomes
20 May 2025 – From EuroPCR 2025
Explore the latest insights into LAA closure from EuroPCR 2025. This session highlights results from the OPTION trial—the largest RCT comparing LAAC (with Watchman FLX) to DOAC therapy in AF patients undergoing ablation. The findings? Comparable stroke prevention at 3 years, with a 56 % reduction...
Cardiogenic shock and high-risk interventions with percutaneous mechanical circulatory support: new evidence and insights
20 May 2025 – From EuroPCR 2025
This EuroPCR 2025 session offers a comprehensive update on cardiogenic shock and high-risk PCI, featuring expert analysis of the DanGer-SHOCK and ECLS-SHOCK trials, new insights one year after DanGer-SHOCK, and practical considerations for managing PCI in patients with severely reduced LVEF. Expect to gain a deeper...
Out of the box: tackling complex peripheral intervention
23 May 2025 – From EuroPCR 2025
Explore unconventional approaches to complex peripheral interventions through case studies involving pulmonary arteriovenous malformations, splenic aneurysms, vascular complications post maxillofacial surgery, and cyanosis in structurally normal hearts, emphasizing diagnostic and therapeutic ingenuity.
Paravalvular leak closure in TMVR
23 May 2025 – From EuroPCR 2025
This session addresses paravalvular leak closure in transcatheter mitral valve replacement, exploring multiple plug techniques, complex leak management, and combined antegrade and retrograde approaches, providing nuanced insights into challenging mitral prosthesis complications.
Calcified un-dilatable lesions in ACS: what should I do?
22 May 2025 – From EuroPCR 2025
Address the challenges of severely calcified undilatable lesions during acute coronary syndrome PCI. This session reviews the impact of coronary calcification on PCI strategy, highlights pitfalls in lesion preparation, and presents detailed case studies demonstrating effective treatment approaches.
PCI in a challenging coronary anatomy
22 May 2025 – From EuroPCR 2025
This session tackles PCI in challenging coronary anatomies, featuring cases with anomalous coronary arteries, complex access routes, and specialized stenting techniques. Learn from experiences managing dual anomalous arteries, navigating to difficult lesions, and applying innovative modified chimney stent methods to restore coronary flow.
Which device for which patient: DES, BRS or DCB?
22 May 2025 – From EuroPCR 2025
This session provides comprehensive guidance on selecting the appropriate device—DES, BRS, or DCB—for individual patients and lesions. It examines patient and lesion characteristics, strengths and limitations of each device type, and regional considerations, illustrated by case presentations demonstrating practical device choice and resolution.
Combined LAA closure and transcatheter mitral valve repair - LIVE Case
22 May 2025 – From EuroPCR 2025
An 82-year-old male patient with a history of PM (pacemaker) implantation in 2024, and ischaemic cardiomyopathy presented with symptomatic heart failure due to severe secondary mitral regurgitation and impaired LV function (EF 40 %). He also presented with recurrent gastro-intestinal bleeding while on DOAC for atrial...
Innovative strategies for coronary interventions
22 May 2025 – From EuroPCR 2025
Explore innovative strategies in coronary interventions, including the EPIC26 sirolimus-eluting stent study, use of percutaneous ventricular assist devices in high-risk patients, the SCORE multicenter study on SeQuent SCB, DCB versus DES for ostial left circumflex lesions, and site-specific antithrombotic therapy outcomes from the DESyne BDS Plus...
Redo TAVI - How to treat different TAVI platforms when they fail
22 May 2025 – From EuroPCR 2025
Understand the complexities of redo TAVI procedures with emphasis on planning, valve platform characteristics, and tailored procedural strategies. This session features cases of redo TAVI for failed short-frame and tall-frame valves, alongside discussions on current evidence gaps guiding optimal management.
Emerging indications for TAVI in 2025
22 May 2025 – From EuroPCR 2025
Prepare for emerging TAVI indications anticipated in 2025. This session reviews clinical cases including asymptomatic severe aortic stenosis, moderate aortic stenosis with heart failure, and severe aortic regurgitation. It discusses supporting evidence from clinical trials, evolving transcatheter technologies, and practical treatment approaches for these novel indications.
High thrombus burden in STEMI
22 May 2025 – From EuroPCR 2025
This session addresses the management of high thrombus burden in STEMI patients. It reviews available tools and strategies for thrombus management, presents multiple case-based discussions illustrating treatment decisions, and explores the evolving role of thrombus aspiration in contemporary practice.
TAVI in women
22 May 2025 – From EuroPCR 2025
Focus on gender-specific considerations in TAVI with this session. Topics include timely management and referral disparities in women with severe aortic stenosis, early outcomes from the LANDMARK trial with latest-generation valves, insights from NAVULTRA comparing valve types, prosthesis-patient mismatch data, and gender differences in right ventricular...
Artificial intelligence in the cathlab
22 May 2025 – From EuroPCR 2025
Delve into the transformative role of artificial intelligence (AI) in the cathlab. This session covers AI applications for vulnerable plaque identification using intracoronary OCT, automated coronary angiogram analysis, rapid AI-based OCT interpretation, AI-enhanced decision-making for PCI optimization, and noninvasive microvascular resistance assessment powered by AI.
Innovations in transcatheter aortic valve devices and techniques
22 May 2025 – From EuroPCR 2025
Explore the latest advancements in transcatheter aortic valve devices and innovative procedural techniques. This session presents initial clinical experiences with new self-expandable valves in small annuli, safety and performance data from the GENESIS-II study on the Hydra valve, and up to 12-month outcomes from the Valvosoft...
